# Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

> **NCT02695459** · PHASE2 · UNKNOWN · sponsor: **The Netherlands Cancer Institute** · enrollment: 39 (actual)

## Conditions studied

- Neuroendocrine Carcinomas

## Interventions

- **DRUG:** cisplatinum and everolimus

## Key facts

- **NCT ID:** NCT02695459
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03-30
- **Primary completion:** 2021-04
- **Final completion:** 2021-08
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2021-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02695459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02695459, "Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02695459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*